Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

(September 28, 2017)

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European... Continue Reading


Delaying Lymph Node Biopsy After Melanoma Diagnosis Does Not Affect Survival Rates

(July 20, 2017)

A lymph node biopsy occurring more than 30 days after diagnosis is unlikely to have an adverse effect on the patient’s overall prognosis Postponing lymph node biopsy more than 30 days after melanoma diagnosis doesn’t adversely impact long-term... Continue Reading


Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

(July 18, 2017)

A clinical trial evaluating Opdivo  (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection has demonstrated a superior recurrence-free survival in... Continue Reading


With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma

(June 15, 2017)

Keytruda® (pembrolizumab) continues to outperform Yervoy® (ipilimumab) as initial treatment of patients with advanced melanoma. Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology... Continue Reading


Check It Out: May is Skin Cancer Awareness Month

(May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading


Combination Immunotherapy with Yervoy and Opdivo Improves Overall Survival Compared to Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

(April 19, 2017)

The first overall survival data from the CheckMate -067 clinical trial evaluating Yervoy (ipilumamab) and Opdivo (nivolumab) combinations has just been reported.  The two-year survival rates were 64% for the Opdivo plus Yervoy combination, 59% for Opdivo... Continue Reading


COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma

(March 15, 2017)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm an estimated 45% of patients who received Tafinlar... Continue Reading


Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients

(October 24, 2016)

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical... Continue Reading


Epacadostat Plus Keytruda® Appears Effective in Melanoma

(October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery,... Continue Reading


Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

(September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination... Continue Reading


Latest Melanoma News By Stage


Recurrent Melanoma

Check It Out: May is Skin Cancer Awareness Month

(May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading


Yervoy Gets Expanded Approval for Earlier-Stage Melanoma

(November 9, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin... Continue Reading


Melanoma Drug T-VEC Receives Recommendation for FDA Approval

(May 1, 2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to... Continue Reading


Coffee May Decrease Risk of Melanoma Skin Cancer

(February 2, 2015)

Coffee might do more than perk you up. New research suggests that coffee drinkers are less likely to develop malignant melanoma, and their risk decreases with every cup they drink.1 Coffee has long been associated with a reduction in the risk of various... Continue Reading


FDA Approves Nivolumab for Advanced Melanoma

(December 23, 2014)

The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab... Continue Reading


More Recurrent Melanoma

Screening/Prevention Melanoma

Check It Out: May is Skin Cancer Awareness Month

(May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading


Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

(May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading


Thin Melanomas Responsible for Many Melanoma Related Deaths

(November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading


MRA Applauds Congress for Getting the Sunscreen Innovation Act over the Goal Line

(November 17, 2014)

(OMNI-CancerConnect) — The Melanoma Research Alliance (MRA) applauds the House for acting on the Senate-passed Sunscreen Innovation Act, clearing the way for the President’s signature. Thanks to the leadership and hard work of Congressmen Ed Whitfield... Continue Reading


Viagra Associated with Increased Risk of Melanoma

(April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially fatal type of skin cancer that begins in the melanocytes,... Continue Reading


More Screening/Prevention Melanoma

Stage III Melanoma

Check It Out: May is Skin Cancer Awareness Month

(May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading


Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients

(October 24, 2016)

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical... Continue Reading


Epacadostat Plus Keytruda® Appears Effective in Melanoma

(October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery,... Continue Reading


Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

(September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination... Continue Reading


Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

(December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The... Continue Reading


More Stage III Melanoma

Stage IV Melanoma

Check It Out: May is Skin Cancer Awareness Month

(May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading


Epacadostat Plus Keytruda® Appears Effective in Melanoma

(October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery,... Continue Reading


Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

(September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination... Continue Reading


3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

(July 21, 2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were... Continue Reading


Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

(December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The... Continue Reading


More Stage IV Melanoma

Stages I-II Melanoma

Check It Out: May is Skin Cancer Awareness Month

(May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading


Injecting of PV-10 is Promising Treatment of Melanoma Lesions

(November 25, 2014)

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently reported. PV-10 is a 10% solution of Rose Bengal,... Continue Reading


Thin Melanomas Responsible for Many Melanoma Related Deaths

(November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading


Progress in the Treatment of Advanced Melanoma and Other Skin Cancers

(November 14, 2014)

By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin cancer are diagnosed each... Continue Reading


Melanoma More Deadly in Young White Men than Women

(August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading


More Stages I-II Melanoma